The Finnish regulatory agency (FIMEA) has approved Kancera AB’s application to conduct a phase I study of KAND-145, the company’s second-generation fractalkine-blocking candidate drug for cancer.
Mvision AI Oy raised €5.4 million (US$5.8 million) in a post seed funding round to help accelerate the development of its artificial intelligence (AI)-powered automatic segmentation software, which automates and standardizes radiotherapy treatment for patients. Mvision aims to make same day cancer treatment a standard globally. The funding was led by J12 Ventures and Voima Ventures.
Herantis Pharma plc has received approval from the Finnish Medicines Agency, Fimea, and an ethics committee for a clinical trial application (CTA) to start clinical development of HER-096 for Parkinson's disease.
If GE Healthcare’s GM of Monitoring Solutions Neal Sandy gets his way, nursing staff will perk up and notice a newly launched wireless patient monitoring system that helps them detect patient deterioration much earlier than periodic, manual monitoring.
Three is the magic number for Finnish companies Abacus Diagnostica Oy, Kaivogen Oy and Labrox Oy as they link up to develop a new diagnostic solution combining antibody and PCR testing on a single device. The three Turku, Finland-based companies said they are joining forces to form a new diagnostics powerhouse, harnessing their own unique expertise. Abacus Diagnostica develops molecular testing and rapid PCR tests while Kaivogen specializes in immunoassays and antibody tests and Labrox on laboratory instruments. All companies have previously collaborated on R&D projects.
LONDON – Startup company Glucomodicum Oy is preparing to commercialize a new technique for the needle-free monitoring of blood glucose levels, applying the principles of magnetohydrodynamics to noninvasively extract interstitial fluid through the skin.
LONDON – Europe has its fourth new fund in less than a month with the launch of Eir Ventures, which arrives on the scene with €76 million (US$85.9 million) to invest in life science startups in the Nordic countries of Norway, Denmark, Sweden and Finland.